A biotech company based out of Ireland saw its shares soar on Tuesday after the company announced that it is discontinuing ...

During a live event, Daniel M. Geynisman, MD, and participants discussed their answers to a poll on which combination to use ...

In the trial, researchers are evaluating Scancell's DNA cancer vaccines SCIB1 and iSCIB1+ alongside immunotherapy.

Enriqueta Felip, MD, PhD, discusses the design of the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab in ...

Updated phase 3 data support pembrolizumab plus concurrent chemoradiotherapy as a standard of care for patients with high-risk, locally advanced cervical cancer, according to Linda Duska, MD.

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic liver cancers, annou ...

Summit Therapeutics' ivonescimab shows potential in cancer treatment, but high risks and valuation concerns suggest caution.

Immunotherapy is key for triple-negative breast cancer, but a new study finds Black women are receiving it less often than White women.

An April 6 article in the WaPo, one of the most recent as the NIH undergoes administrative changes, claims, “A big step forward in cancer therapy has been slowed by layoffs and ...

Adding pembrolizumab to docetaxel did not significantly improve outcomes in previously treated patients with mCRPC.

Converging computational and laboratory technologies are helping anti-cancer immune responses hit their target more ...

The US giants which supply vital new medicines to UK patients face disruption from Donald Trump’s trade barriers, experts ...